Literature DB >> 8897561

Long-term therapy with enalapril in patients with nephrotic-range proteinuria.

W Proesmans1, I V Wambeke, M V Dyck.   

Abstract

The effect of enalapril on urinary protein excretion and renal function was studied in six paediatric patients with various renal diseases causing nephroticrange proteinuria. In three younger children (aged 7-9 years) with steroid-resistant nephrotic syndrome, enalapril at a dose of 0.5 mg/kg per day given for 24 months yielded a temporary reduction of proteinuria in one child, a moderate and steady decrease in another and a complete disappearance of proteinuria in the third. Three adolescents, aged 17 years, took enalapril for 24 months at a dose of 20 mg/day. We observed no effect on proteiuria in one patient with Alport syndrome, a complete disappearance of urinary protein in one patient with membranoproliferative glomerulonephritis and a moderate decrease in the third patient who had idiopathic steroid-resistant nephrotic syndrome. Enalapril therapy resulted in an important reduction of proteinuria in two patients and a moderate decrease in three others. However this therapy was accompanied by a fall in glomerular filtration in all subjects, which was very marked in two patients. This fall in glomerular filtration may, however, simply reflect the natural course of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897561     DOI: 10.1007/s004670050166

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.

Authors:  H Trachtman; B Gauthier
Journal:  J Pediatr       Date:  1988-02       Impact factor: 4.406

2.  The renal functional and structural consequences of corticosteroid and angiotensin-converting enzyme inhibitor therapy in chronic puromycin aminonucleoside nephropathy.

Authors:  H Trachtman; R Del Pizzo; E Valderrama; B Gauthier
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

3.  Therapeutic implications of converting-enzyme inhibitors in renal disease.

Authors:  S Anderson; B M Brenner
Journal:  Am J Kidney Dis       Date:  1987-07       Impact factor: 8.860

4.  Reduction of proteinuria by angiotensin converting enzyme inhibition.

Authors:  J E Heeg; P E de Jong; G K van der Hem; D de Zeeuw
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

5.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

Authors:  S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Effect of dipyridamole treatment on proteinuria in pediatric renal disease.

Authors:  N Ueda; S Kawaguchi; Y Niinomi; T Nonoda; M Ohnishi; S Ito; T Yasaki
Journal:  Nephron       Date:  1986       Impact factor: 2.847

7.  Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model.

Authors:  F Terzi; H Beaufils; D Laouari; M Burtin; C Kleinknecht
Journal:  Kidney Int       Date:  1992-08       Impact factor: 10.612

8.  Long-term comparison between captopril and nifedipine in the progression of renal insufficiency.

Authors:  P Zucchelli; A Zuccalà; M Borghi; M Fusaroli; M Sasdelli; C Stallone; G Sanna; R Gaggi
Journal:  Kidney Int       Date:  1992-08       Impact factor: 10.612

9.  Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.

Authors:  D S Milliner; B Z Morgenstern
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

10.  Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria.

Authors:  M Praga; E Hernández; C Montoyo; A Andrés; L M Ruilope; J L Rodicio
Journal:  Am J Kidney Dis       Date:  1992-09       Impact factor: 8.860

View more
  12 in total

1.  Progression of chronic renal failure in children with dysplastic kidneys.

Authors:  Claudia González Celedón; María Bitsori; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2007-03-23       Impact factor: 3.714

2.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Mabel Missoni; Clarisa Vezzani
Journal:  Pediatr Nephrol       Date:  2012-12-20       Impact factor: 3.714

Review 3.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

4.  Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome.

Authors:  María Gracia Caletti; Horacio Lejarraga; Diana Kelmansky; Mabel Missoni
Journal:  Pediatr Nephrol       Date:  2004-06-18       Impact factor: 3.714

5.  Antiproteinuric effects of enalapril and losartan: a pilot study.

Authors:  Colin Thomas White; Catherine Fiona Macpherson; Robert Morrison Hurley; Douglas George Matsell
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

6.  Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.

Authors:  Maria Van Dyck; Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

7.  Enalapril in children with Alport syndrome.

Authors:  Willem Proesmans; Maria Van Dyck
Journal:  Pediatr Nephrol       Date:  2004-01-24       Impact factor: 3.714

8.  Drugs controlling proteinuria of patients with Alport syndrome.

Authors:  Jian-Guo Li; Jie Ding; Fang Wang; Hong-Wen Zhang
Journal:  World J Pediatr       Date:  2009-11-13       Impact factor: 2.764

9.  Enalapril dosage in steroid-resistant nephrotic syndrome.

Authors:  Arvind Bagga; Basanagoud D Mudigoudar; Pankaj Hari; Vandita Vasudev
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

10.  Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.

Authors:  Howard Trachtman; Suzanne Vento; Debbie Gipson; Larysa Wickman; Jennifer Gassman; Melanie Joy; Virginia Savin; Michael Somers; Maury Pinsk; Tom Greene
Journal:  BMC Nephrol       Date:  2011-02-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.